This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
DaVita Kidney Care Opens 150000-Square-Foot Campus in DeLand
by Zacks Equity Research
DaVita's (DVA) dialysis care in the United States gets a boost; market prospects solid.
Omnicell Continues to Pursue Buyouts, Costs on the Rise
by Zacks Equity Research
Omnicell (OMCL) progresses well with its strategy to grow inorganically. Rising operating expenses a concern.
AngioDynamics (ANGO) to Acquire RadiaDyne, Boost Oncology
by Zacks Equity Research
AngioDynamics' (ANGO) agreement to acquire RadiaDyne is expected to close by the end of September. The RadiaDyne acquisition will expand the Oncology segment.
Cardiovascular Systems Portfolio Strong, Competition Rife
by Zacks Equity Research
Cardiovascular Systems (CSII) suffers a long history of net loss since its launch in 1989 with no immediate solution in sight.
Pacific Biosciences (PACB) Up as VGP Picks Flagship Sequel
by Zacks Equity Research
Pacific Biosciences (PACB) sees a slew of developments in its coveted SMRT Sequel platform.
DENTSPLY Launches Azento, Improves Digital Implant Workflow
by Zacks Equity Research
DENTSPLY's (XRAY) Azento is a unique dental platform that will help dentists select the best-fitting implant, optimal implant positioning and feasible healing environment.
Here's Why You Should Invest in Penumbra (PEN) Stock Now
by Zacks Equity Research
The market is quite upbeat about Penumbra's (PEN) recently-closed buyout of a controlling stake in MVI Health, aimed at capturing the great potential of virtual reality application.
Here's Why You Should Retain IDEXX (IDXX) in Your Portfolio
by Zacks Equity Research
IDEXX (IDXX) continues to see strong organic growth. Adverse currency movement is a concern.
Allscripts' Sunrise Abstracting Selected by Wyckoff Heights
by Nabaparna Bhattacharya
Allscripts' (MDRX) Sunrise Abstracting Solution gets picked by Wyckoff Heights Medical Center. The platform complements Allscripts Sunrise electronic health record unit.
Medtronic (MDT) Initiates ONYX ONE- Clear Study on DAPT
by Zacks Equity Research
Following a DAPT interruption at one month on patients with a next generation DES, the Onyx ONE Clear Study by Medtronic (MDT) investigates risk of cardiac death, heart attack and stent thrombosis.
Here's Why You Should Retain QIAGEN (QGEN) in Your Portfolio
by Zacks Equity Research
A tough competitive landscape and strong reliance on relationships with collaborative partners is a major deterrent to QIAGEN (QGEN). The company's increased focus on the NGS portfolio is a positive.
Stryker (SYK) to Acquire Invuity, Boost Surgical Portfolio
by Zacks Equity Research
Stryker (SYK) on an acquisition spree; latest buyout likely to aid its array of surgical instruments.
Genomic Health (GHDX) Hits a 52-Week High: What's Driving It?
by Zacks Equity Research
Genomic Health (GHDX) sees increasing private coverage for the Oncotype DX GPS test within the prostate cancer space.
Here's Why You Should Hold On to DaVita (DVA) Stock Now
by Zacks Equity Research
Strong prospects in the Kidney Care segment to drive DaVita (DVA) stock over the long haul.
Integra Lifesciences Picked for Healogics iSupply Program
by Zacks Equity Research
Integra Lifesciences' (IART) selection as a key provider for cellular-based tissue products within Healogics' new iSupply program to boost the top line.
Varian Up on Tie-Up With Kenya's Mediheal Group of Hospitals
by Zacks Equity Research
Varian's (VAR) advanced cancer care solution prospects bright in the global market.
Here's Why You Should Invest in Surmodics (SRDX) Stock Now
by Zacks Equity Research
Continuous focus on R&D and a raised guidance for fiscal 2018 make Surmodics (SRDX) a lucrative pick for investors.
IDEXX Gains Ground on Solid CAG Business Amid Forex Woes
by Zacks Equity Research
IDEXX (IDXX) continues to see strong organic growth, driven by solid sales at the CAG business. However, unfavorable currency movement remains a concern.
Here's Why You Should Hold On to Quest Diagnostics (DGX) Now
by Zacks Equity Research
Tough competitive landscape and reimbursement issues are major deterrents to Quest Diagnostics' (DGX) top line in the near term. The company's focus on promising areas to drive growth is a positive.
Boston Scientific to Boost MedSurg Unit Via Augmenix Buyout
by Zacks Equity Research
Boston Scientific (BSX) continues to adopt organic as well as inorganic means to boost top line.
Penumbra Launches Reperfusion Catheters, Boosts Neuro Unit
by Zacks Equity Research
Penumbra (PEN) adopts initiatives to boost the highest revenue generating Neuro business.
Genomic Health Prostate Cancer Business Solid, Cost Woes Stay
by Zacks Equity Research
Within the prostate cancer space, Genomic Health (GHDX) is seeing increasing private coverage for the Oncotype DX GPS test. Costs and operating expenses continue to rise.
Here's Why You Should Invest in athenahealth (ATHN) Now
by Zacks Equity Research
Focus on cloud-based services and a lifted guidance for 2018 make athenahealth (ATHN) an attractive pick.
Varian's (VAR) ProBeam System Gets Picked by Delray Medical
by Zacks Equity Research
Varian Medical's (VAR) coveted ProBeam platform sees a slew of developments; market prospects solid.
Here's Why You Should Hold on to Abiomed (ABMD) for Now
by Zacks Equity Research
Abiomed's (ABMD) margin continues to remain pressed; an upbeat view for fiscal 2019 encourages.